JO2990B1 - مركبات بروبان دائري - Google Patents
مركبات بروبان دائريInfo
- Publication number
- JO2990B1 JO2990B1 JOP/2011/0289A JOP20110289A JO2990B1 JO 2990 B1 JO2990 B1 JO 2990B1 JO P20110289 A JOP20110289 A JO P20110289A JO 2990 B1 JO2990 B1 JO 2990B1
- Authority
- JO
- Jordan
- Prior art keywords
- hydrogen atom
- independently represent
- atom
- cyclopropane compound
- alkyl group
- Prior art date
Links
- -1 Cyclopropane compound Chemical class 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
يتمثل المركب cyclopropane في الصيغة التالية (A) أو ملح (salt) مقبول دوائيا منه حيث يمكن الانتفاع منه في معالجة اضطراب النوم الذي يفيد فيه معارضة مستقبل orexin، مثل الأرق: Q يمثل -CH- أو ذرة nitrogen، R1a وR1b كلاهما على حدة يمثل مجموعة C1-6 alkyl، إلخ، R1c يمثل ذرة hydrogen، إلخ، R2a، R2b، R2c وR2d كل منهم على حدة يمثل ذرة hydrogen، ذرة halogen، مجموعة C1-6 alkyl، إلخ، R3a، R3b وR3c كل منهم على حدة يمثل ذرة hydrogen، ذرة halogen، إلخ، R3d يمثل ذرة hydrogen، إلخ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534210P | 2010-09-22 | 2010-09-22 | |
| JP2010211629 | 2010-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2990B1 true JO2990B1 (ar) | 2016-09-05 |
Family
ID=45873858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2011/0289A JO2990B1 (ar) | 2010-09-22 | 2011-09-20 | مركبات بروبان دائري |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8268848B2 (ar) |
| EP (1) | EP2626350B1 (ar) |
| JP (1) | JP4944286B1 (ar) |
| KR (1) | KR101458007B1 (ar) |
| CN (1) | CN103153963B (ar) |
| AR (1) | AR083060A1 (ar) |
| AU (1) | AU2011304285B2 (ar) |
| BR (1) | BR112013006594B1 (ar) |
| CA (1) | CA2811895C (ar) |
| CL (1) | CL2013000784A1 (ar) |
| DK (1) | DK2626350T3 (ar) |
| ES (1) | ES2540851T3 (ar) |
| IL (1) | IL225437A (ar) |
| JO (1) | JO2990B1 (ar) |
| MA (1) | MA34609B1 (ar) |
| MX (1) | MX2013003218A (ar) |
| MY (1) | MY160969A (ar) |
| NZ (1) | NZ609313A (ar) |
| PE (1) | PE20131162A1 (ar) |
| PL (1) | PL2626350T3 (ar) |
| PT (1) | PT2626350E (ar) |
| RS (1) | RS54101B1 (ar) |
| RU (1) | RU2571414C2 (ar) |
| SG (1) | SG188585A1 (ar) |
| SI (1) | SI2626350T1 (ar) |
| TW (1) | TWI516484B (ar) |
| UA (1) | UA108510C2 (ar) |
| WO (1) | WO2012039371A1 (ar) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104114524B (zh) | 2012-02-17 | 2016-08-17 | 卫材R&D管理有限公司 | 用于食欲肽-2受体拮抗剂的合成的方法和化合物 |
| WO2014081619A1 (en) * | 2012-11-20 | 2014-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| RU2681937C2 (ru) * | 2014-08-06 | 2019-03-14 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ получения пиримидин-1-олового соединения и его промежуточного соединения |
| ES2843952T3 (es) | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| JP6885560B2 (ja) | 2015-10-29 | 2021-06-16 | 国立大学法人 筑波大学 | モルヒナン誘導体及びその医薬用途 |
| EP4056180A1 (en) | 2016-05-12 | 2022-09-14 | Eisai R&D Management Co., Ltd. | Methods of treating circadian rhythm sleep disorders |
| WO2019024845A1 (zh) * | 2017-08-01 | 2019-02-07 | 苏州科睿思制药有限公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| KR20220008804A (ko) | 2019-05-15 | 2022-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 오렉신-2 수용체 길항제의 제조에 유용한 방법 및 화합물, 및 약간의 불순물을 갖는 렘보렉산트 |
| CN114096251A (zh) * | 2019-06-26 | 2022-02-25 | 卫材R&D管理有限公司 | 用于治疗睡眠问题的莱博雷生 |
| EP4073058A1 (en) * | 2019-12-11 | 2022-10-19 | Teva Czech Industries s.r.o. | Solid state form of lemborexant |
| BR112022012246A2 (pt) | 2019-12-20 | 2022-08-30 | Eisai R&D Man Co Ltd | Uso de lemborexant para tratar insônia |
| TW202140014A (zh) | 2020-01-16 | 2021-11-01 | 日商衛材R&D企管股份有限公司 | 萊博雷生的原料藥及含有其的醫藥組成物 |
| WO2021205648A1 (ja) * | 2020-04-10 | 2021-10-14 | 国立大学法人東海国立大学機構 | 精神障害患者の客観的睡眠評価方法 |
| JP2024527024A (ja) | 2021-07-26 | 2024-07-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患に伴う不規則睡眠・覚醒リズム障害及び概日リズム睡眠障害を治療する方法における使用のためのレンボレキサント |
| WO2023178702A1 (zh) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | 莱博雷生及其中间体化合物的制备方法 |
| WO2023178693A1 (zh) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | 一种莱博雷生及其中间体的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| CA2220036A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
| HU226524B1 (en) * | 1996-12-10 | 2009-03-30 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane derivatives and the use thereof for producing pharmaceutical compositions having melatonergic activity |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| WO2005118548A1 (en) | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| BRPI0515571A (pt) * | 2004-09-23 | 2008-07-29 | Pfizer Prod Inc | agonistas de receptor de trombopoetina |
| EP1871752A4 (en) * | 2005-04-12 | 2009-09-30 | Merck & Co Inc | ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR |
| CN101155792A (zh) * | 2005-04-12 | 2008-04-02 | 默克公司 | 氨基丙氧基苯基增食欲素受体拮抗剂 |
| JP2006328057A (ja) * | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| WO2007105177A1 (en) | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| BRPI0716532A2 (pt) | 2006-09-11 | 2013-09-24 | Glaxo Group Ltd | compostos azabicÍclios como inidores de reabsorÇço de monoaminas |
| KR20090077051A (ko) * | 2006-09-29 | 2009-07-14 | 액테리온 파마슈티칼 리미티드 | 3-아자-비시클로[3.1.0]헥산 유도체 |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| AR064561A1 (es) * | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| CA2700025A1 (en) | 2007-09-21 | 2009-04-02 | Sanofi-Aventis | (cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| CA2745433A1 (en) * | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| US20120165339A1 (en) * | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
-
2011
- 2011-09-20 JO JOP/2011/0289A patent/JO2990B1/ar active
- 2011-09-20 MA MA35823A patent/MA34609B1/fr unknown
- 2011-09-20 RS RS20150418A patent/RS54101B1/en unknown
- 2011-09-20 SI SI201130507T patent/SI2626350T1/sl unknown
- 2011-09-20 US US13/237,205 patent/US8268848B2/en active Active
- 2011-09-20 EP EP11826816.8A patent/EP2626350B1/en active Active
- 2011-09-20 AR ARP110103428A patent/AR083060A1/es active IP Right Grant
- 2011-09-20 JP JP2012500752A patent/JP4944286B1/ja active Active
- 2011-09-20 BR BR112013006594-0A patent/BR112013006594B1/pt active IP Right Grant
- 2011-09-20 MY MYPI2013000954A patent/MY160969A/en unknown
- 2011-09-20 KR KR1020137009631A patent/KR101458007B1/ko active IP Right Grant
- 2011-09-20 CA CA2811895A patent/CA2811895C/en active Active
- 2011-09-20 PT PT118268168T patent/PT2626350E/pt unknown
- 2011-09-20 SG SG2013019880A patent/SG188585A1/en unknown
- 2011-09-20 NZ NZ609313A patent/NZ609313A/en unknown
- 2011-09-20 PE PE2013000532A patent/PE20131162A1/es active IP Right Grant
- 2011-09-20 DK DK11826816.8T patent/DK2626350T3/en active
- 2011-09-20 UA UAA201304939A patent/UA108510C2/ru unknown
- 2011-09-20 CN CN201180045556.7A patent/CN103153963B/zh active Active
- 2011-09-20 ES ES11826816.8T patent/ES2540851T3/es active Active
- 2011-09-20 MX MX2013003218A patent/MX2013003218A/es active IP Right Grant
- 2011-09-20 RU RU2013117464/04A patent/RU2571414C2/ru active
- 2011-09-20 AU AU2011304285A patent/AU2011304285B2/en active Active
- 2011-09-20 PL PL11826816T patent/PL2626350T3/pl unknown
- 2011-09-20 TW TW100133754A patent/TWI516484B/zh active
- 2011-09-20 WO PCT/JP2011/071325 patent/WO2012039371A1/ja active Application Filing
-
2013
- 2013-03-21 CL CL2013000784A patent/CL2013000784A1/es unknown
- 2013-03-21 IL IL225437A patent/IL225437A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2990B1 (ar) | مركبات بروبان دائري | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MY185217A (en) | Analogs of glucagon exhibiting gip receptor activity | |
| MX2011013016A (es) | Derivados de aminopirrolidinona y usos de los mismos. | |
| MX2013006304A (es) | Analogos de glucagon que exhiben actividad del receptor gip. | |
| GEP201706616B (en) | Hydrazide containing nuclear transport modulators and usage thereof | |
| ZA201200389B (en) | Crystalline forms of n-[3-fluoro-4-([6-(methyloxy)-7-[(morpholin-4ylpropyl)oxy}]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide | |
| MX2015011180A (es) | Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc). | |
| PH12016500480A1 (en) | Antibacterial 2h-indazole derivatives | |
| MX337392B (es) | Sujetador de seguridad. | |
| WO2010102154A3 (en) | Biaryl oxyacetic acid compounds | |
| DK2569178T3 (da) | Indretning til justering af positionen og fastgørelse af et låseorgan på en bærer med udligning af spillerum | |
| JO2930B1 (ar) | عملية جديدة لتركيب إيفابرادين وأملاح إضافة منها مع حامض مقبول دوائياً | |
| GB201020397D0 (en) | Compounds | |
| JO2854B1 (ar) | طريقة جديدة لتركيب الأنفابرادين وأملاحه المضافة مع حمض يكون مقبولا صيدلانيا. | |
| IN2015DN00961A (ar) | ||
| TN2013000119A1 (en) | Cyclopropane compounds | |
| MX2011010358A (es) | Derivados de 2-hidroxietil-1h-quinolin-2-ona y sus analogos azaisostericos con actividad antibacteriana. | |
| CY1116553T1 (el) | Ενωση κυκλοπροπανιου | |
| MY170662A (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| SA113340412B1 (ar) | عملية جديدة لتصنيع إيڤابرادين وأملاح إضافة منه مع حمض مقبول صيدلانياً | |
| PT2621891T (pt) | Polimorfos de cloridrato de 4-metilbenzoato de 4-[2- dimetilamino-1-(1-hidroxiciclohexil)etil]fenilo, métodos para a preparação dos mesmos e utilização dos mesmos | |
| IN2012DN03169A (ar) | ||
| TH92860A (ar) |